Vistagen Therapeutics, Inc. Annual Net Income (Loss) Attributable to Parent in USD from 2009 to 2023

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Vistagen Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2009 to 2023.
  • Vistagen Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending December 31, 2024 was -$14.1M, a 122% decline year-over-year.
  • Vistagen Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending December 31, 2024 was -$47.3M, a 47.5% decline year-over-year.
  • Vistagen Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$29.4M, a 50.4% increase from 2022.
  • Vistagen Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$59.2M, a 24% decline from 2021.
  • Vistagen Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$47.8M, a 166% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)
* An asterisk sign (*) next to the value indicates that the value is likely invalid.